drugset / Trial / NCT07355335
Ziftomenib + Mezigdomide in Adolesc. and Adults w/ R/R AML
Phase 1
Not yet recruiting
24 enrolled
Massachusetts General Hospital
Bristol-Myers Squibb · collabKura Oncology, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and tolerability of mezigdomide in combination with ziftomenib in adolescent and adult participants with either KMT2A-rearranged (KMT2A-r) or NPM1-mutant relapsed or refractory acute myeloid leukemia (AML).
Timeline
- Start
- 2026-07-09
- Primary completion
- 2027-07-01
- Completion
- 2028-01-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mezigdomide | Small molecule | — | Oral |
| Subject | Ziftomenib | Small molecule | — | Oral |